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Abstract
Purpose: To assess the radiation dose delivered to the heart and ipsilateral lung during accelerated
partial breast brachytherapy using a MammoSite™ applicator and compare to those produced by
whole breast external beam radiotherapy (WBRT).
Materials and methods: Dosimetric analysis was conducted on patients receiving MammoSite
breast brachytherapy following conservative surgery for invasive ductal carcinoma. Cardiac dose
was evaluated for patients with left breast tumors with a CT scan encompassing the entire heart.
Lung dose was evaluated for patients in whom the entire lung was scanned. The prescription dose
of 3400 cGy was 1 cm from the balloon surface. MammoSite dosimetry was compared to simulated
WBRT fields with and without radiobiological correction for the effects of dose and fractionation.
Dose parameters such as the volume of the structure receiving 10 Gy or more (V10) and the dose
received by 20 cc of the structure (D20), were calculated as well as the maximum and mean doses
received.
Results: Fifteen patients were studied, five had complete lung data and six had left-sided tumors
with complete cardiac data. Ipsilateral lung volumes ranged from 925–1380 cc. Cardiac volumes
ranged from 337–551 cc. MammoSite resulted in a significantly lower percentage lung V30 and lung
and cardiac V20 than the WBRT fields, with and without radiobiological correction.
Conclusion:  This study gives low values for incidental radiation received by the heart and
ipsilateral lung using the MammoSite applicator. The volume of heart and lung irradiated to clinically
significant levels was significantly lower with the MammoSite applicator than using simulated WBRT
fields of the same CT data sets.
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Background
Accelerated partial breast irradiation (APBI) is increas-
ingly being used as an alternative to whole breast irradia-
tion following wide local excision in selected patients
with early stage low-risk breast cancer [1]. The technique
is appealing to both physicians and patients due to the
decrease in overall treatment time and the reduction in
treatment volume. The majority of published series of
patients treated with APBI have used brachytherapy [1-
17]. Initial data using multiple interstitial catheters using
either high dose rate (HDR) or low dose rate (LDR) brach-
ytherapy has shown promising results [12,15,17]. How-
ever, interstitial implants can be complex and operator-
dependant therefore the MammoSite applicator (Hologic,
Bedford, Massachusetts, USA) was developed to make
APBI with brachytherapy more accessible and less inva-
sive. Since this is a new technology, there is a paucity of
long-term follow-up using this technique. The prospective
series with the longest follow-up to date using the Mam-
moSite catheter show low levels of ipsilateral breast recur-
rence with minimal incidence of tumor bed recurrence
[2,14,16].
Direct dosimetric comparisons have been made between
different forms of APBI using intensity modulated radio-
therapy (IMRT), 3-dimensional conformal external beam
radiotherapy (3DCRT) and MammoSite brachytherapy
[18]. Dose comparisons have also been made between
patients undergoing whole breast external beam radio-
therapy (EBRT) and ABPI, simulating the position of a
MammoSite catheter within the breast on EBRT CT treat-
ment planning scans [19]. However, data has not been
published on direct comparisons of the normal tissue
dosimetry for whole breast EBRT and APBI in patients
who have a MammoSite applicator in situ. This study
examines the dosimetry of the heart and ipsilateral lung in
patients undergoing APBI with a MammoSite catheter.
The organs at risk (OAR) dosimetry when using the Mam-
moSite catheter was compared with that of reconstructed
EBRT fields, taking into consideration the radiobiological
characteristics of the MammoSite catheter and the effect of
an increased dose per fraction in the APBI treatment
regime.
Methods
Patient eligibility
Fifteen patients were prospectively enrolled in an institu-
tional review board approved feasibility study. All
patients underwent breast-conserving surgery with partial
mastectomy and negative sentinel lymph node biopsy or
axillary dissection for T1/T2 invasive ductal carcinoma
between September 2003 and February 2005. The Mam-
moSite applicator was sited in the tumor cavity either
under direct vision intra-operatively or using ultrasound
guidance post-operatively.
Treatment planning
All patients underwent a CT treatment-planning scan fol-
lowing MammoSite balloon insertion. In addition the
patients received daily conventional simulation films
using fluoroscopy to ensure consistency in balloon diam-
eter, see figure 1. The CT images were transferred to Plato
brachytherapy planning system (version 14.2.6, Nuclet-
ron BV, Veenendaal, The Netherlands). A dose of 3.4 Gy
per fraction for a 10 fraction treatment course was pre-
scribed at 1 cm from the balloon surface. The dose was
optimized to 6 points at +/- x, y, z axis positions. Seven to
nine dwell positions with 5 mm spacing were used to
improve dose homogeneity and decrease the effect of
source anisotropy [20], see figure 2.
The source strength, dwell positions and times were trans-
ferred with the CT images to the Eclipse treatment plan-
ning system (Brachytherapy planning 6.5, Varian Medical
Systems, Palo Alto, California, USA) for OAR contouring
and dose volume histogram (DVH) analysis. The lungs
were contoured from apex to diaphragm, to represent the
whole ipsilateral lung within the parietal pleura. The
whole heart was contoured, to represent the myocardium.
AP radiograph demonstrating the image reviewed for daily  quality assurance measurements of the MammoSite balloon  diameter Figure 1
AP radiograph demonstrating the image reviewed 
for daily quality assurance measurements of the 
MammoSite balloon diameter. The catheter contains a 
radio-opaque strand with markers at intervals of 1 cm.Radiation Oncology 2008, 3:39 http://www.ro-journal.com/content/3/1/39
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In the absence of intravenous contrast administration, it
was not possible to define the left ventricle or coronary
arteries. The balloon surface was contoured manually. All
contouring was performed by the same practitioner (AJS).
Using the same CT treatment planning data, with the
inflated MammoSite catheter in situ, a course of fraction-
ated whole breast EBRT was planned using the Pinnacle
system (External Beam Planning 6.5 build 7.3.10, Varian
Medical Systems, Palo Alto, California, USA). Tangent
fields were set up for each patient using standard medial
(patient midline) and lateral (mid-axillary line) borders
with appropriate collimator angulations to minimize ipsi-
lateral lung volume irradiation. Appropriate anterior and
inferior flash was used. Typical tangential weightings and
wedge compensators were employed to achieve reasona-
ble homogeneity of dose across the breast tissue. A dose of
50 Gy in 25 fractions over 5 weeks was modeled. DVHs
were prepared for the tissues under study. Each patient
served as their own internal control with respect to anat-
omy and therefore EBRT dosimetry and MammoSite
dosimetry was compared using identical CT data sets. Fig-
ures 3 and 4 demonstrate the MammoSite and EBRT treat-
ment fields and their relationship to lung dosimetry
(figures 3A and 3B) and cardiac dosimetry (4A and 4B).
WBRT was chosen as a comparator rather than other par-
tial breast irradiation techniques because the only alterna-
tive treatment to partial breast irradiation with
brachytherapy using the MammoSite catheter at this insti-
tution was WBRT. Partial breast radiotherapy using EBRT
was not offered as an alternative at this institution at this
time.
Axial CT images demonstrating the isodose pattern of the MammoSite balloon and surrounding critical normal tissues Figure 2
Axial CT images demonstrating the isodose pattern of the MammoSite balloon and surrounding critical nor-
mal tissues.Radiation Oncology 2008, 3:39 http://www.ro-journal.com/content/3/1/39
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Axial CT images to demonstrate the lung dosimetry at the same level on the same patient showing the MammoSite dosimetry  (3A) and the simulated EBRT field dosimetry (3B) Figure 3
Axial CT images to demonstrate the lung dosimetry at the same level on the same patient showing the Mam-
moSite dosimetry (3A) and the simulated EBRT field dosimetry (3B).
A
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Axial CT images to demonstrate cardiac dosimetry at the same level on the same patient showing the MammoSite dosimetry  (4A) and the simulated EBRT field dosimetry (4B) Figure 4
Axial CT images to demonstrate cardiac dosimetry at the same level on the same patient showing the Mam-
moSite dosimetry (4A) and the simulated EBRT field dosimetry (4B). The heart is shown in the red colorwash and 
the lungs in the green colorwash.
A
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Dosimetric analysis
Dose to the heart was evaluated for all patients with left
breast tumors who had a CT scan encompassing the entire
heart. Dose to the ipsilateral lung was evaluated for all
patients for whom the lung was scanned from apex to dia-
phragm. DVH analysis was performed and the following
parameters were assessed for the MammoSite plan and for
the EBRT plan. The maximum (Dmax) and mean
(Dmean) doses for each structure were measured. For the
heart the highest dose received by 20 cc and 30 cc of the
whole heart volume (the D20 and D30 respectively) was
measured The volume of the heart receiving a dose of 5 Gy
and higher, 10 Gy and higher and 20 Gy and higher (V5,
V10 and V20 respectively) were calculated as an absolute
volume and as a percentage of the total cardiac volume.
The highest dose received by 5 cc (D5) of the ipsilateral
lung was measured. The volume of the ipsilateral lung
receiving a dose of 10 Gy, 20 Gy and 30 Gy or higher (V10,
V20, V30 respectively) was calculated as an absolute vol-
ume and as a percentage of the total lung volume. These
dosimetric parameters were chosen because they have
been shown to correlate with late toxicity in patients
undergoing radiotherapy for non small cell lung cancer
(NSCLC) [21-24]. The cardiac parameters were chosen to
reflect available data regarding the risk of cardiac toxicity
following radiation exposure in atomic bomb survivors
and following radiotherapy for peptic ulcer disease [25-
27].
By convention in breast dosimetry studies the standard
nomenclature used is V10 to define the volume receiving
10 Gy and D10 to define the dose received by 10 cc of
organ volume. This differs from the standard nomencla-
ture for brachytherapy dosimetry in other areas of the
body where the V10 would refer to the volume of tissue
receiving 10% or greater of the dose. If comparing the data
within this paper to published literature in other primary
disease sites, these nomenclature changes should be
borne in mind.
Radiobiologic estimations
It could be considered that use of the standard breast radi-
otherapy dosimetry reporting parameters for the Mam-
moSite balloon may not be radiobiologically comparable
to EBRT since the MammoSite balloon employs a larger
dose per fraction than the EBRT. To account for the effect
of an increased dose per fraction, the radiobiological
equivalents of the standard breast dose reporting parame-
ters were calculated using the linear quadratic equation
[28]. Using an alpha/beta (α/β) ratio of 3.6 Gy for breast
tumor tissue [29] and 3 Gy for late effects to the heart and
lung [30], it was calculated that a MammoSite V4.5 may
be equivalent to an EBRT V5, a MammoSite V9 may be
equivalent to an EBRT V10, a MammoSite V16.5 may be
equivalent to an EBRT V20 and a MammoSite V23.5 may
be equivalent to an EBRT V30 (see appendix 1 for biolog-
ically equivalent dose (BED) equations). This correction
does not account for the dose inhomogeneity produced
by a brachytherapy source. However, these effects are
likely to be most marked in close proximity to the source
and decrease with increasing distance from the source.
The radiobiological effect of an accelerated treatment
course was not included in the calculation as it is generally
felt that treatment time does not make a radiobiological
difference in breast tumors [29]. These calculations also
do not use a dose reduction for HDR because these dose
reductions may not be as accurate as distance from the
catheter increases. If the HDR dose reduction is not used,
the most conservative estimate of dose equivalence is
obtained since with the HDR dose reduction the dosimet-
ric parameters would be closer to the EBRT measurements
than the radiobiologically adjusted dosimetric parame-
ters.
Statistical Analysis
The dosimetric parameters outlined above were summed
and the median calculated. The significance of the differ-
ence between the groups was assessed using paired two-
tailed Student's t-test. The paired t-test was chosen because
there is a one-to-one pairing between the patient with the
MammoSite plan and the EBRT plan because the same CT
data sets were used for both analyses.
Results
Five patients had complete ipsilateral lung CT data and six
patients undergoing left breast treatment had complete
heart CT data. The median ipsilateral lung volume was
985 cc (range 925–1380 cc). The median cardiac volume
was 428 cc (range 337–551 cc).
When comparing the dose received by the ipsilateral lung
using the MammoSite catheter and WBRT, the volume of
lung irradiated to 20 Gy or more and 30 Gy or more was
significantly lower using the MammoSite catheter than
WBRT, see table 1. This difference was maintained when
the radiobiological effects of an increased dose per frac-
tion were calculated for the V23.5/V30 parameter but only
when the volume was considered as a percentage of the
whole lung volume for the V16/V20 parameter, see table
2. There was no statistically significant difference in the
maximum or mean dose delivered to the lung, though the
highest dose received by 5 cc of lung was significantly
lower using the MammoSite catheter. There was no statis-
tically significant difference in the volume of lung irradi-
ated to low doses (10 Gy and greater).
When comparing the dose received by the heart using the
MammoSite catheter and WBRT, the MammoSite catheter
delivered a significantly lower maximum dose thanRadiation Oncology 2008, 3:39 http://www.ro-journal.com/content/3/1/39
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WBRT, see table 1. The volume of the heart irradiated to
20 Gy or more was significantly higher using WBRT than
the MammoSite catheter, see table 1. This statistically sig-
nificant difference was maintained when the radiobio-
logical effects of an increased dose per fraction were
calculated, see table 2. There was no statistically signifi-
cant difference in the volume of the heart irradiated to 10
Gy and greater and no difference in the mean cardiac
dose. When much lower doses to the heart were examined
(V5) it could be seen that the WBRT delivered significantly
Table 1: A comparison of doses to the heart and ipsilateral lung dosimetry from the MammoSite catheter and external beam 
radiotherapy using the standard dosimetric parameters.
Dosimetric Parameters MammoSite (34 Gy/10#/1 week) External Beam (50 Gy/25#/5 weeks) p-value
Mean Range Mean Range
Lung n = 5
Dmean 4.2 Gy 2.1–5.6 Gy 6.5 Gy 2.6–11.8 Gy p = 0.18
Dmax 31 Gy 6.3–45.7 Gy 51.6 Gy 49.7–55.9 Gy p = 0.06
V30 (cc) 2 cc 0–7.2 cc 86.7 cc 31.5–184 cc p = 0.04*
V30 (%) 0.2% 0–0.5% 8.3% 2.3–19.9% p = 0.04*
V20 (cc) 13.4 cc 0–34.6 cc 105 cc 46.1–205 cc p = 0.04*
V20 (%) 1.3% 0–2.5% 10% 3.3–22.2% p = 0.04*
V10 (cc) 83.3 cc 0–170 cc 133.6 cc 67.8–235 cc p = 0.31
V10 (%) 8% 0–13.3% 12.8% 4.9–25.4% p = 0.20
D5 11.3 Gy 3.9–15.3 Gy 49.9 Gy 47.5–53.4 Gy p = 0.005*
Heart
Dmean 3.8 Gy 3.1–4.8 Gy 3.5 Gy 1.1 – 5.1 Gy p = 0.63
Dmax 16.6 Gy 10.6–27.2 Gy 44.1 Gy 15.5–51.8 Gy p = 0.004*
V20 (cc) 0.3 cc 0–1.5 cc 15.6 cc 0–23.9 cc p = 0.008*
V20 (%) 0.1% 0–0.3% 3.7% 0–5.3% p = 0.001*
V10 (cc) 10.6 cc 0.2–33.6 cc 22.9 cc 0.3–39.0 cc p = 0.07
V10 (%) 2.5% 0–7.5% 5.4% 0.1–8.7% p = 0.07
V5 (cc) 83.8 cc 46.9–145.0 cc 41.5 cc 3.1–82.3 cc p = 0.006*
V5 (%) 19.8% 11.0–32.2% 9.6% 0.8–18.3% p = 0.008*
D20 8.5 Gy 6.4–11.9 Gy 15.3 Gy 2.3–24.3 Gy p = 0.10
D30 7.5 Gy 5.8–10.4 Gy 7.6 Gy 2–14.0 Gy p = 0.94
* represents a statistically significant p-value
Table 2: A comparison of doses to the heart and ipsilateral lung dosimetry from the MammoSite catheter and external beam 
radiotherapy using the radiobiologically adjusted dosimetric parameters.
MammoSite (34 Gy/10#/1 week) External Beam (50 Gy/25#/5 weeks) p-value
Mean Range Mean Range
Lung
V23.5 7 cc 0–20.4 cc V30 86.7 cc 31.5–184 cc p = 0.05*
V23.5 0.7% 0–1.5% V30 8.3% 2.3–19.9% p = 0.03*
V16.5 23.6 cc 0–57.9 cc V20 105 cc 46.1–205 cc p = 0.06
V16.5 2.3% 0–4.2% V20 10% 3.3–22.2% p = 0.03*
V9 98.1 cc 0–201.7 cc V10 133.6 cc 67.8–235 cc p = 0.48
V9 9.4% 0–13.3% V10 12.8% 4.9–25.4% p = 0.26
Heart
V16.5 1.2 cc 0–5.2 cc V20 15.7 cc 0–23.9 cc p = 0.009*
V16.5 0.3% 0–1.2% V20 3.7% 0–5.3% p = 0.01*
V9 15.9 cc 2.1–47.4 cc V10 22.9 cc 0.3–39.0 cc p = 0.34
V9 3.7% 0.5–10.5% V10 5.4% 0.1–8.7% p = 0.35
V4.5 105.7 cc 64.5–173.5 cc V5 41.47 cc 3.1–82.3 cc p = 0.001*
V4.5 25.0% 15.1–38.5% V5 9.6% 0.8–18.3% p = 0.002*
* represents a statistically significant p-valueRadiation Oncology 2008, 3:39 http://www.ro-journal.com/content/3/1/39
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lower radiation than the MammoSite catheter, see table 1.
This significant difference was maintained when radiobio-
logical adjustment was undertaken, see table 2.
Discussion
This study gives low values of radiation dose using the
MammoSite catheter for both heart and lung. In all cases
less than 25% of the ipsilateral lung received less than 20
Gy, which has been shown to correlate with a lower inci-
dence of late toxicity in lung cancer patients [21-24]. The
maximum dose received by the heart and the maximum
dose received by 5 cc of lung were significantly lower with
the MammoSite technique than EBRT. The MammoSite
catheter irradiated a significantly lower volume of the
heart and lung to higher doses than EBRT. The volume of
lung irradiated to lower doses was similar with both tech-
niques. However, the volume of heart irradiated to lower
doses was significantly higher with the MammoSite cath-
eter than WBRT. When radiobiological adjustment was
performed, these significant differences were maintained.
The planning target volume (PTV) irradiated is much
lower with the MammoSite catheter than EBRT and it
could be argued that the MammoSite technique would be
expected to deliver a lower dose of radiation to critical
normal tissues. However, it is interesting that the volumes
of heart and lung irradiated to moderately low doses are
not significantly different, possibly due to the radial dose
distribution using single catheter brachytherapy. It is also
interesting that the volume of heart irradiated to very low
doses is higher with the MammoSite technique than
WBRT. In certain clinical situations, the MammoSite cath-
eter may deliver higher doses of radiation to clinically sig-
nificant levels than WBRT, such as a left-sided implant
lying directly on the chest wall over the heart. In these sit-
uations it may be preferable to use multi-catheter brachy-
therapy implants which give the ability to sculpt the dose
around organs at risk. The ability to identify these patients
prior to implant placement would be valuable.
Early studies of breast cancer radiotherapy showed an
increased cardiac mortality in patients undergoing irradi-
ation of the left breast [31,32]. In Hodgkin's disease medi-
astinal irradiation exceeding 30 Gy (V30) is associated
with an increased risk of death from cardiac disease, how-
ever in the present study no patient undergoing Mam-
moSite brachytherapy had any cardiac volume receiving
over 30 Gy; in fact only 1 patient had irradiation to the
heart exceeding 20 Gy. Due to the long latency of cardiac
morbidity following radiotherapy for breast cancer and
the relatively new advent of image-guided radiotherapy
planning, no distinct CT-based dosimetric parameters for
the heart have been correlated with late effect following
breast cancer radiotherapy. Although the risk of late cardi-
ovascular events and irradiation to higher doses has long
been associated with EBRT, more recently there has been
evidence that there is an increased risk of radiation-
induced heart disease at lower levels of exposure [25,27].
Also the risk of radiation induced tumors following expo-
sure to low doses of radiation must always be remem-
bered [33].
The percentage of the left ventricle (LV) irradiated corre-
lates with the development of perfusion defects on cardiac
SPECT (single photon emitting computed tomography)
scanning [34]. But it is unknown whether a potentially
reversible cardiac perfusion defect is associated with later
myocardial morbidity. An elevated body mass index
(BMI) is also associated with increased LV perfusion
defects, possibly because these patients have significantly
higher rates of radiotherapy set-up errors resulting in
increased LV irradiation [34]. Brachytherapy eliminates
set-up errors due to the delivery of dose within catheters
fixed in the tissue, which may make it a preferred option
in women with early breast cancer and a high BMI.
In patients with lung cancer, it has been shown that late
toxicity rates increase as the volume of lung receiving over
20 Gy increases [21,22]. When this parameter was
assessed by Lind et al. in patients undergoing whole breast
EBRT for breast cancer, the same association was seen
[35]. Therefore it is recommended that the pulmonary
V20 be kept below 30%. Increasing age and a pre-existing
decrease in pulmonary capacity was also shown to influ-
ence late pulmonary toxicity [35]. This emphasizes the
importance of considering all associated co-morbidities
when assessing the risk of late toxicities rather than just
isolated dosimetric parameters.
When the dosimetry of the MammoSite catheter has been
compared to other EBRT techniques, both partial and
whole breast, the majority of studies have shown lower
volumes of heart and lung receiving high doses of radia-
tion with the MammoSite catheter [19,36,37]. Patients
who had a higher cardiac dose using the MammoSite cath-
eter than a whole breast IMRT technique appeared to be
those whose tumor bed lay close to the chest wall [36].
However, a definitive "safe" distance from the chest wall
could not be determined. In the current study, it could be
subjectively assessed that in women with large breasts,
with the catheter lying far from the chest wall, the cardiac
doses were minimal or undetectable. The cardiac dose is
dependent on factors which can be modified by a change
in the radiation technique such as the position of the cath-
eter within the breast, proximity to the chest wall or
medial versus lateral placement and also factors which
cannot be modified such as the position of the heart
within the thorax which can vary greatly from patient to
patient.Radiation Oncology 2008, 3:39 http://www.ro-journal.com/content/3/1/39
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Khan et al. showed that the MammoSite catheter resulted
in significantly higher cardiac V5 (5% or greater of pre-
scription dose) due to the ability to shape the dose using
EBRT techniques. Although the current study showed
much lower values for cardiac V10 and V20 (and their
radiobiologically adjusted equivalents) using the Mam-
moSite catheter than would be extrapolated from Khan et
al.'s results, the decrease in irradiation to lower doses may
still have marked clinical significance [25-27]. The confor-
mation of the MammoSite catheter with dose delivery via
a single catheter means that there is no opportunity for
"dose sculpting" (conforming the dose to the PTV) to
decrease the dose received by the heart in situations where
the balloon lies closer to the chest wall without compro-
mising PTV coverage. This problem may be overcome in
the future with the introduction of single entry insertion
catheters with multiple channels such as the ClearPath™
catheter [38].
Limitations of this study include the use of the CT treat-
ment planning images with the MammoSite balloon
inflated for the EBRT dosimetry which may result in a
larger breast volume than if the EBRT was planned with-
out the MammoSite catheter in situ. However, this
increased volume is more likely to affect hot spots within
the breast than heart and lung doses since these are
mainly affected by curvature of the chest wall and the
position of the tumor bed within the breast. In contrast,
in studies where the MammoSite catheter is simulated
within a seroma cavity on an EBRT CT planning scan,
treatment volumes and thus normal tissue dosimetry may
be underestimated because the MammoSite balloon
causes tissue displacement and stretching resulting in a
larger PTV than the PTV encompassed by 1 cm around the
seroma [39,40]. The effect of this displacement could be
difficult to predict, even with the use of a pre-MammoSite
insertion CT scan. The CT images were obtained without
the use of an angled breast board, which could result in
higher doses delivered using the EBRT plans than if it
modeled using standard treatment techniques. However,
this was compensated for within the EBRT planning proc-
ess with the use of collimator angulation. Cardiac blocks
were not placed for the EBRT plans. Use of these may have
resulted in slightly lower cardiac doses, as could other
techniques such as active breathing control.
The dosimetric parameters that have been assessed are
based on large datasets of external beam radiotherapy
patients who would have received treatment using con-
ventional fractionation schemes of 1.8–2 Gy per fraction.
Where radiobiological correction has been made, it must
be remembered that the BED equation does not fully
account for the effects of a higher dose per fraction for the
critical normal structures. The effect on the heart and
lungs of a higher dose per fraction are unknown, espe-
cially in the clinical scenario of a patient proceeding to
potentially cardiotoxic chemotherapy.
Conclusion
This small subset study gives low values for cardiac and
lung normal tissue doses using the MammoSite applicator
using both standard measuring parameters and biologi-
cally equivalent parameters. When compared to whole
breast EBRT fields, the volume of the heart and lung
receiving higher doses of radiation is significantly lower
using the MammoSite catheter. The volume of heart
receiving low doses of radiation is significantly higher
using the MammoSite catheter. It is unknown which radi-
ation exposure may be the most clinically significant,
higher doses or lower doses. The volume of lung receiving
low doses of radiation is similar with both techniques.
Long-term prospective follow-up would be of value in this
group of patients to correlate dose received with late tox-
icity paying attention to the late effects of an increased
dose per fraction using this technique. Ongoing research
will focus on OAR dosimetry using EBRT and IMRT tech-
niques versus MammoSite and other brachytherapy tech-
niques, with particular focus on the effect of differing
position of the MammoSite catheter within the breast.
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Appendix 1
Biologic equivalent dose (BED) calculations
BED = d × n [1 + (d/α/β)]
Where d = dose per fraction
n = total number of fractions delivered
nd = D where D = total dose
If the α/β for late toxicity to the heart and lungs is taken to
be 3 Gy [30] the following equations were derived to cal-
culate an equivalent probability of late effects:
For a V10 with a total dose of 50 Gy/25 fractions, the dose
per fraction is 0.4 GyRadiation Oncology 2008, 3:39 http://www.ro-journal.com/content/3/1/39
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Thus EBRT BED = 10 × (1 + 0.4/3)
= 11.3
MS BED = 9 × (1 + 0.9/3)
= 11.7 Gy3
Hence a V9 using 34 Gy/10 fractions is equivalent to a V10
using 50 Gy/25 fractions (the equivalent dosimetry points
were calculated to the nearest 0.5 Gy for ease of measure-
ment).
V5 EBRT BED = 5 × (1 + 0.2/3)
= 5.3 Gy3
V4.5 equivalent MS BED = 4.5 × (1 + 0.45/3)
= 5.2 Gy3
V20 EBRT BED = 20 × (1 + 0.8/3)
= 25.3 Gy3
V16.5 equivalent MS BED = 16.5 × (1 + 1.65/3)
= 25.6 Gy3
V30 EBRT BED = 30 × (1 + 1.2/3)
= 42 Gy3
V23.5 equivalent MS BED = 23.5 × (1 + 2.35/3)
= 41.9 Gy3
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